Back to search results

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Metastatic Pancreatic Adenocarcinoma · Locally Advanced Pancreatic Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

    Contact: Study coordinator (HCC Clinical Trials Office) · hcc-clinical-trials@musc.edu · 843-792-9321
    Contact: Principal Investigator (Albert Lockhart, MD)

  • Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States

    Contact: Study coordinator (HCC Clinical Trials Office) · hcc-clinical-trials@musc.edu · 843-792-9321
Study leads

  • Albert Lockhart, MD

    Principal Investigator

    Medical University of South Carolina

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)